TY - JOUR
T1 - ONO-4057, a novel, orally active leukotriene B4 antagonist
T2 - Effects on LTB4-induced neutrophil functions
AU - Kishikawa, K.
AU - Tateishi, N.
AU - Maruyama, T.
AU - Seo, R.
AU - Toda, M.
AU - Miyamoto, T.
PY - 1992/10
Y1 - 1992/10
N2 - ONO-4057(5-[2-(2-Carboxyethyl)-3-{6-( 4-methoxyphenyl )-5E-hexenyl} oxyphenoxy ] valeric acid), an orally active leukotriene B4(LTB4) antagonist, displaced the binding of [3H] LTB4 to the LTB4 receptor in human neutrophil (Ki = 3.7±0.9 nM). ONO-4057 inhibited the LTB4-induced rise in cytosolic free calcium (the concentration causing 50% inhibition (IC50) = 0.7±0.3μM) and inhibited human neutrophil aggregation, chemotaxis or degranulation induced by LTB4 (IC50 = 3.0±0.1, 0.9±0.1 and 1.6±0.1μM) without showing any agonist activity at concentration up to 30μM. ONO-4057 did not inhibit fMLP or C5a-induced neutrophil activation at concentrations up to 30μM. In the in vivo study, ONO-4057 given orally, prevented LTB4-induced transient neutropenia or intradermal neutrophil migration in guinea pig (the dose causing 50% efficacy (ED50) = 25.6mg/kg or 5.3mg/kg). Furthermore, ONO-4057 given topically, suppressed phorbol-12-myristate-13-acetate (PMA)-induced neutrophil infiltration in guinea pig ear (the effective dose = 1 mg/ear). These results indicate that ONO-4057 is a selective and orally active LTB4 antagonist and may be a potential candidate for the treatment of various inflammatory diseases.
AB - ONO-4057(5-[2-(2-Carboxyethyl)-3-{6-( 4-methoxyphenyl )-5E-hexenyl} oxyphenoxy ] valeric acid), an orally active leukotriene B4(LTB4) antagonist, displaced the binding of [3H] LTB4 to the LTB4 receptor in human neutrophil (Ki = 3.7±0.9 nM). ONO-4057 inhibited the LTB4-induced rise in cytosolic free calcium (the concentration causing 50% inhibition (IC50) = 0.7±0.3μM) and inhibited human neutrophil aggregation, chemotaxis or degranulation induced by LTB4 (IC50 = 3.0±0.1, 0.9±0.1 and 1.6±0.1μM) without showing any agonist activity at concentration up to 30μM. ONO-4057 did not inhibit fMLP or C5a-induced neutrophil activation at concentrations up to 30μM. In the in vivo study, ONO-4057 given orally, prevented LTB4-induced transient neutropenia or intradermal neutrophil migration in guinea pig (the dose causing 50% efficacy (ED50) = 25.6mg/kg or 5.3mg/kg). Furthermore, ONO-4057 given topically, suppressed phorbol-12-myristate-13-acetate (PMA)-induced neutrophil infiltration in guinea pig ear (the effective dose = 1 mg/ear). These results indicate that ONO-4057 is a selective and orally active LTB4 antagonist and may be a potential candidate for the treatment of various inflammatory diseases.
UR - http://www.scopus.com/inward/record.url?scp=0026641477&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026641477&partnerID=8YFLogxK
U2 - 10.1016/0090-6980(92)90002-B
DO - 10.1016/0090-6980(92)90002-B
M3 - Article
C2 - 1332129
AN - SCOPUS:0026641477
VL - 44
SP - 261
EP - 275
JO - Prostaglandins
JF - Prostaglandins
SN - 0090-6980
IS - 4
ER -